公开(公告)号：EP2350294A2

公开(公告)日：2011-08-03

申请号：EP09752581.0

申请日：2009-10-27

申请人： Baxter International Inc. ,  Baxter Healthcare SA

发明人： SCHWARZ, Hans-Peter ,  MUCHITSCH, Eva-Maria ,  TURECEK, Peter

IPC分类号： C12N15/85 ,  A01K67/027 ,  A61K49/00

CPC分类号： A61K49/0008 ,  A01K67/027 ,  A01K67/0275 ,  A01K67/0276 ,  A01K2217/052 ,  A01K2217/054 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/03 ,  A01K2267/0306 ,  A01K2267/0325 ,  A01K2267/0381 ,  C12N15/8509

摘要： The invention relates to the development of an animal model for testing various agents in the treatment of a clotting disorder. More specifically, the invention relates to the use of ultra-large molecular weight multimers of von Willebrand factor (VWF) in various mouse strains to induce thrombotic thrombocytopenic purpura (TTP)-like symptoms for the development of a mouse model of TTP. The invention also provides methods for generating such animal disease models and screening methods for identifying biologically active compounds which are effective in the treatment of TTP.

摘要翻译： 本发明涉及用于测试治疗凝血障碍的各种药剂的动物模型的开发。 更具体地说，本发明涉及von Willebrand因子（VWF）的超大分子量多聚体在各种小鼠品系中的应用，以诱导血小板减少性紫癜（TTP）样症状，用于开发TTP小鼠模型。 本发明还提供了产生用于鉴定有效治疗TTP的生物活性化合物的这种动物疾病模型和筛选方法的方法。

公开(公告)号：EP2462231A2

公开(公告)日：2012-06-13

申请号：EP10744782.3

申请日：2010-08-04

申请人： Baxter International Inc ,  Baxter Healthcare SA

发明人： TURECEK, Peter ,  AHMAD, Raffi, Udin ,  GRITSCH, Herbert ,  MUCHITSCH, Eva-Maria ,  SCHWARZ, Hans-Peter

IPC分类号： C12N15/85 ,  A01K67/027

CPC分类号： C12N15/8509 ,  A01K67/0275 ,  A01K2217/052 ,  A01K2217/054 ,  A01K2217/072 ,  A01K2227/105 ,  A01K2267/03

摘要： The present invention relates, generally, to a transgenic non-human animal model of hemophilia A, wherein the transgenic animal is deficient in endogenous Factor VIII and endogenous von Willebrand Factor, and methods to treat hereditary or acquired hemophilia A or von Willebrand Disease (VWD) by administration of exogenous human VWF.